U073 Off-label Use of Biologics and New Medications
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
During the session, off-label use of biologic and other specialty drugs will be reviewed. The aim is to help the practioner optimize the delivery of appropriate treatments for patients. Medications to be discussed include TNF-alpha inhibitors, anti-IL17 antibodies, anti-IL23 biologics, dupilumab, apremilast, and JAK inhibitors.
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 CCP Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Use dupilumab for bullous pemphigoid.
Use apremilast for seborrheic dermatitis and lichen planus.
Discuss the use of anti-IL17 and anti-IL23 biologics for hidradenitis suppurativa.
SCHEDULE
11:30 PM
Off-label Use of Biologics and New Medications
SPEAKERS
Edita Newton, PhD, MD, FAAD
David Rosmarin, MD, FAAD
Jay Wolverton, MD, FAAD
SPEAKER DISCLOSURES
Edita Newton, PhD, MD, FAAD
No financial relationships exist with ineligible companies.
David Rosmarin, MD, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Abcuro, Inc. – Consultant(Honoraria); Almirall – Consultant (1099 relationship)(Honoraria); AltruBio Inc. – Consultant(Honoraria); Amgen – Speaker(Honoraria); Arena Pharmaceuticals – Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Celgene – Investigator(Grants/Research Funding); Celgene Corporation – Advisory Board(Honoraria), Speaker(Honoraria); Concert Pharmaceuticals – Consultant(Honoraria), Data Safety Monitoring Board(Honoraria); CSL Behring – Consultant(Honoraria); Dermavant Sciences – Advisory Board(Honoraria), Speaker(Honoraria); Dermira – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding), Other(Other Financial Benefit), Speaker(Honoraria); Janssen Biotech – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Consultant(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Merck & Co., Inc – Investigator(Grants/Research Funding); Nektar Therapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); RAPT Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Recludix Pharma – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Revolo Therapeutics – Consultant(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant(Honoraria); UCB – Advisory Board(Honoraria); Viela Bio – Advisory Board(Honoraria); Zura Bio – Consultant (1099 relationship)(Honoraria);
Jay Wolverton, MD, FAAD
No financial relationships exist with ineligible companies.